The Epilepsy market report also offers comprehensive insights into the Epilepsy market size, share, Epilepsy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Epilepsy market size growth forward.
Some of the key highlights from the Epilepsy Market Insights Report:
Several key pharmaceutical companies, including non Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others, are developing novel products to improve the Epilepsy treatment outlook.
In January 2025, Alembic received FDA approval for its generic version of AbbVie’s Depakote Sprinkle (divalproex sodium delayed-release capsules, 125 mg). Divalproex sodium is an anti-epileptic drug used to treat epilepsy, including complex partial seizures, simple and complex absence seizures, and as an adjunct therapy for multiple seizure types.
In December 2024, Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced that the FDA granted seven years of orphan drug exclusivity (ODE) to Libervant® (diazepam) Buccal Film. This treatment is designed for managing acute episodes of seizure clusters or acute repetitive seizures in epilepsy patients aged 2 to 5 years, providing a novel option for these urgent scenarios.
DelveInsight estimates that in 2023, there were around 7 million diagnosed prevalent cases of epilepsy across the 7MM. Of these, 48% were in the US, 39% in the EU4 and the UK, and 13% in Japan.
The epilepsy market is projected to grow steadily, with an estimated compound annual growth rate (CAGR) of approximately 7% from 2024 to 2034. This growth is driven by the introduction of innovative therapies, including LIBERVANT (diazepam buccal film), XEN1101, COMFYDE (carisbamate), Lorcaserin (E2023), and Soticlestat (TAK-935), among others.
Most existing antiepileptic drugs (AEDs) primarily manage seizures rather than offering a cure and often cause cardiovascular and respiratory side effects. For patients with refractory epilepsy, these treatments are often insufficient, leaving many to experience seizures despite using multiple drug combinations. This underscores a significant unmet need in therapy.
The epilepsy market is becoming increasingly competitive with the development of new therapies and innovative treatment approaches. Recent approvals have focused on specific patient populations, such as those with acute repetitive seizures, partial onset seizures, and Lennox-Gastaut syndrome (LGS).
Additionally, a strong drug development pipeline targeting ion channels, receptors, or neurotransmitters involved in seizure production, transmission, or modulation has the potential to reshape market dynamics during the forecast period.
As per DelveInsight analysis, the Epilepsy market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Epilepsy Market Landscape
Epilepsy Overview
The World Health Organization (WHO) defines epilepsy as a chronic, non-communicable neurological disorder that affects individuals of all ages and contributes significantly to the global disease burden. It is characterized by recurrent, unprovoked seizures caused by sudden, uncontrolled electrical disturbances in the brain. These seizures can manifest as convulsions, altered consciousness, unusual sensations, or behavioral changes, with symptoms varying based on the brain’s affected region and the extent of the disturbance.
Epilepsy disrupts normal neuronal activity due to physiological changes such as impaired Na+/K+ ATPase activity, reduced GABA release, and calcium overload, leading to symptoms like strange sensations, muscle spasms, convulsions, and sometimes loss of consciousness. In many cases, the exact cause remains unknown, resulting in idiopathic epilepsy.
According to the International League Against Epilepsy (ILAE) classification, seizures are categorized as:
Focal onset seizures: Originate in a localized brain area (e.g., simple and complex focal seizures).
Generalized onset seizures: Affect both brain hemispheres from the start (e.g., tonic-clonic, myoclonic, atonic, and absence seizures). Seizures are further classified as cryptogenic (unknown cause) or symptomatic (caused by identifiable factors like brain injury or infection). Certain epilepsy types and syndromes, such as Lennox–Gastaut Syndrome (LGS) and Dravet Syndrome, are linked to specific clinical features.
Risk factors for epilepsy include age, family history, head injuries, childhood seizures, dementia, brain infections, and stroke.
Do you know the treatment paradigms for different countries? Download our Epilepsy Market Sample Report
Epilepsy Epidemiology Insights
In the 7MM, there were approximately 7 million diagnosed prevalent cases of epilepsy in 2023, with this figure projected to grow at a CAGR of 0.4% by 2034.
In the US, around 3.3 million people were diagnosed with epilepsy in 2023, with 14% of cases in children and 86% in adults. The total number of cases is expected to rise by 2034.
Meanwhile, in the EU4 and the UK, there were about 1.3 million male cases and 1.5 million female cases of epilepsy in 2023, and these figures are also anticipated to increase over the forecast period.
Epilepsy Epidemiology Segmentation
DelveInsight’s Epilepsy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Epilepsy historical patient pools and forecasted Epilepsy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Epilepsy Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
Epilepsy Prevalence
Age-Specific Epilepsy Prevalence
Gender-Specific Epilepsy Prevalence
Diagnosed and Treatable Cases of Epilepsy
Visit for more @ Epilepsy Epidemiological Insights
Epilepsy Market Outlook
The epilepsy treatment approach includes three main strategies: pharmacotherapy, surgery, and alternative treatments such as neurostimulation, ketogenic diets, and lifestyle changes. Treatment plans are tailored to the patient’s condition and severity of the disorder.
Pharmacotherapy with antiepileptic drugs (AEDs) is the most common treatment and is highly effective, controlling seizures in about 70% of patients. AEDs work by preventing excessive electrical signals in the brain. Factors influencing drug choice include seizure type, epilepsy syndrome, side effects, patient age, gender, medical history, and cost. Treatment may involve monotherapy or combination therapy with multiple AEDs.
A wide range of AEDs has been approved by regulatory authorities, including carbamazepine, valproic acid, levetiracetam, lamotrigine, and cannabidiol, among others. Many of these drugs now have generic versions due to patent expirations. AEDs target seizures through various mechanisms, such as blocking sodium or calcium channels, enhancing GABA-A receptor activity, or modulating potassium channels. For instance:
– Sodium channel blockers: Phenytoin, carbamazepine, lamotrigine.
– Calcium channel blockers: Ethosuximide, valproic acid, zonisamide.
– GABA enhancers: Phenobarbital, benzodiazepines.
– Other actions: Felbamate (NMDA receptor blocker), topiramate (AMPA receptor blocker), and ezogabine (potassium channel opener).
Treatment strategies also consider rare epilepsy syndromes (e.g., Dravet syndrome, Lennox-Gastaut syndrome) and seizure types (focal and generalized). While AEDs are the cornerstone of epilepsy management, surgical or alternative therapies may be explored for refractory cases.
Epilepsy Marketed Drugs
LIBERVANT (diazepam buccal film): Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)
EPIDIOLEX/EPIDYOLEX (cannabidiol): Jazz Pharmaceuticals
XCOPRI/ONTOZRY (cenobamate): SK Biopharmaceutical/Angelini Pharma/Ono Pharmaceutical
AFINITOR DISPERZ/VOTUBIA (everolimus): Novartis
Epilepsy Emerging Drugs
XEN1101/Azetukalner: Xenon Pharmaceuticals
BHV-7000 (KB-3061): Biohaven Pharmaceuticals/Knopp Biosciences
Soticlestat (TAK-935): Takeda/Ovid Therapeutics
Epilepsy Key Companies
Xenon Pharmaceuticals
Aquestive Therapeutics
Atnahs Pharma (Pharmanovia)
Takeda
Ovid Therapeutics
SK Biopharmaceuticals (SK Life Science)
Eisai
Biohaven Pharmaceuticals
Knopp Biosciences
UCB Pharma
Alexza Pharmaceuticals
Neurocrine Biosciences
Idorsia Pharmaceuticals
Equilibre Biopharmaceuticals, and others
For more information, visit Epilepsy Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Epilepsy Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Epilepsy, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Epilepsy epidemiology in the 7MM
Epilepsy marketed and emerging therapies
Epilepsy companies
Epilepsy market drivers and barriers
Table of Contents:
1 Epilepsy Market Key Comprehensive Insights
2 Epilepsy Market Report Introduction
3 Competitive Intelligence Analysis for Epilepsy
4 Epilepsy Market Analysis Overview at a Glance
5 Executive Summary of Epilepsy
6 Epilepsy Epidemiology and Market Methodology
7 Epilepsy Epidemiology and Patient Population
8 Epilepsy Patient Journey
9 Epilepsy Treatment Algorithm, Epilepsy Current Treatment, and Medical Practices
10 Key Endpoints in Epilepsy Clinical Trials
11 Epilepsy Marketed Therapies
12 Epilepsy Emerging Therapies
13 Epilepsy: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Epilepsy
16 Epilepsy Market Key Opinion Leaders Reviews
18 Epilepsy Market Drivers
19 Epilepsy Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Epilepsy Epidemiology 2034
DelveInsight’s “Epilepsy – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Epilepsy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Epilepsy Pipeline 2024
“Epilepsy Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Epilepsy market. A detailed picture of the Epilepsy pipeline landscape is provided, which includes the disease overview and Epilepsy treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
